#BEGIN_DRUGCARD DB02153

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
3-Sulfino-L-alanine
3-sulphino-L-alanine
L-Cysteinesulfinic acid

# CAS_Registry_Number:
1115-65-7

# ChEBI_ID:
16345

# Chemical_Formula:
C3H7NO4S

# Chemical_IUPAC_Name:
(2R)-2-amino-3-[(R)-sulfino]propanoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
3-Sulfinoalanine

# HET_ID:
CSD

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C3H7NO4S/c4-2(3(5)6)1-9(7)8/h2H,1,4H2,(H,5,6)(H,7,8)/t2-/m0/s1

# InChI_Key:
InChIKey=ADVPTQAUNPRNPO-REOHCLBHSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C00606

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2153

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
153.157

# Molecular_Weight_Mono:
153.009578407

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1I8B

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.1

# Predicted_LogS:
-0.7

# Predicted_Water_Solubility:
3.02e+01 g/l

# Primary_Accession_No:
DB02153

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
1549098

# PubChem_Substance_ID:
46505410

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01032

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
N[C@@H](C[S@@](O)=O)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:51 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_10_Cellular_Location:
Cytoplasmic

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
Not Available

# Drug_Target_10_GenBank_ID_Gene:
BA000033

# Drug_Target_10_GenBank_ID_Protein:
21204141

# Drug_Target_10_GeneCard_ID:
Not Available

# Drug_Target_10_Gene_Name:
def

# Drug_Target_10_Gene_Sequence:
>552 bp
TTAAACTTCTACAGCATCTGTATGTGGTTGTAATGGGTGATCTTTGTCAATGTGATCATA
GAACATTACACCATTTAAATGGTCAATTTCATGTTGGAAAACAATTGCTGGATATCCTTT
TAGACGTAATTGTATATCATTACCTTCGATGTCTTTGGCTTTAATTGTAATTCTATTATG
ACGGTGAACTAGACCAGCAACATTATCATCGACACTAAGGCAACCTTCACCAGTTGGTAA
ATAAGCTTCTTGAACGCTATGACTTACAATTTTTGGGTTCACAAGCATATAGTCATAAGA
TTTGCCACTGCCATCATCTGGTATTAAAACAGCAATCATACGTTTAGAAATATTAATTTG
AGGTGCAGCCAAACCAACGCCTGAACGTAAACCATATCGTTTCGCGATTTCCTCATCTTG
ACTATTTACTAAAAACTCTCTCATGGCGATTAATGTTTCTTTTTCTTCTTTAGTTAATGG
TAATTCTAACTCAGCTGCTTTTTGACGCAAAGTTGGATGACCATCTCTAATGATGTCTTT
CATTGTTAACAT

# Drug_Target_10_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_10_General_References:
12044378	Baba T, Takeuchi F, Kuroda M, Yuzawa H, Aoki K, Oguchi A, Nagai Y, Iwama N, Asano K, Naimi T, Kuroda H, Cui L, Yamamoto K, Hiramatsu K: Genome and virulence determinants of high virulence community-acquired MRSA. Lancet. 2002 May 25;359(9320):1819-27.

# Drug_Target_10_HGNC_ID:
Not Available

# Drug_Target_10_HPRD_ID:
Not Available

# Drug_Target_10_ID:
3004

# Drug_Target_10_Locus:
Not Available

# Drug_Target_10_Molecular_Weight:
20560

# Drug_Target_10_Name:
Peptide deformylase

# Drug_Target_10_Number_of_Residues:
183

# Drug_Target_10_PDB_ID:
1LQW

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF01327	Pep_deformylase

# Drug_Target_10_Protein_Sequence:
>Peptide deformylase
MLTMKDIIRDGHPTLRQKAAELELPLTKEEKETLIAMREFLVNSQDEEIAKRYGLRSGVG
LAAPQINISKRMIAVLIPDDGSGKSYDYMLVNPKIVSHSVQEAYLPTGEGCLSVDDNVAG
LVHRHNRITIKAKDIEGNDIQLRLKGYPAIVFQHEIDHLNGVMFYDHIDKDHPLQPHTDA
VEV

# Drug_Target_10_Reaction:
formyl-L-methionyl peptide + H2O = formate + methionyl peptide

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions

# Drug_Target_10_SwissProt_ID:
Q8NX78

# Drug_Target_10_SwissProt_Name:
DEF_STAAW

# Drug_Target_10_Synonyms:
EC 3.5.1.88
PDF
Polypeptide deformylase

# Drug_Target_10_Theoretical_pI:
6.03

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_11_Cellular_Location:
Cytoplasmic

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
Not Available

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
Not Available

# Drug_Target_11_GenBank_ID_Gene:
AF012735

# Drug_Target_11_GenBank_ID_Protein:
Not Available

# Drug_Target_11_GeneCard_ID:
Not Available

# Drug_Target_11_Gene_Name:
Not Available

# Drug_Target_11_Gene_Sequence:
>1245 bp
ATGATCTCACTCGCCGACCTCCAGCGCCGCATCGAAACGGGCGAGCTGTCGCCTAACGCA
GCCATCGCCCAGTCGCACGCGGCGATCGAGGCGCGGGAGAAGGAGGTCCATGCCTTCGTC
CGCCACGACAAGTCGGCAAGAGCGCAAGCCTCCGGCCCGCTGCGCGGTATCGCCGTCGGC
ATCAAGGACATCATCGACACCGCCAACATGCCCACCGAGATGGGCTCGGAGATCTATCGC
GGCTGGCAGCCGCGCAGCGACGCGCCTGTCGTGATGATGCTGAAGCGGGCGGGGGCCACC
ATCATCGGCAAGACCACCACCACGGCGTTCGCCTCGCGCGATCCGACGGCGACGCTCAAT
CCGCACAATACCGGCCATTCCCCGGGCGGCTCGTCCTCGGGCTCGGCGGCGGCGGTCGGC
GCCGGCATGATCCCGCTGGCGCTGGGCACCCAGACCGGCGGCTCGGTGATCCGGCCCGCC
GCCTATTGCGGGACGGCCGCGATCAAGCCGTCGTTCCGCATGCTGCCGACGGTCGGCGTG
AAGTGCTATTCGTGGGCGCTCGACACGGTCGGCCTGTTCGGCGCGCGCGCGGAGGATCTC
GCGCGCGGACTGCTGGCGATGACCGGCCGCAGCGAATTCTCCGGCATCGTCCCGGCCAAG
GCACCGCGCATCGGCGTGGTCAGGCAGGAGTTCGCCGGCGCTGTCGAGCCGGCGGCCGAG
CAGGGCCTGCAAGCCGCGATCAAGGCGGCCGAGCGGGCCGGGGCCAGTGTTCAGGCCATC
GATCTGCCCGAGGCGGTGCATGAGGCCTGGCGCATCCATCCCATCATCCAGGATTTCGAG
GCGCATCGCGCGCTCGCCTGGGAGTTTTCCGAGCATCACGACGAGATCGCGCCGATGCTG
CGCGCCAGTCTCGATGCGACGGTCGGGCTCACGCCGAAGGAATATGACGAGGCGCGCCGG
ATCGGCCGCCGTGGCCGCCGCGAGCTTGGCGAAGTGTTCGAGGGCGTCGACGTGCTCTTG
ACCTATTCGGCGCCGGGCACCGCGCCGGCCAAGGCTCTCGCGAGCACCGGCGACCCTCGC
TACAACCGGCTCTGGACGCTGATGGGCAATCCTTGCGTCAACGTGCCGGTGCTGAAGGTC
GGTGGCCTGCCGATCGGCGTGCAGGTGATCGCGCGCTTCGGCAACGACGCACATGCGCTT
GCGACGGCGTGGTTCCTGGAGGATGCGCTGGCGAAATCAGGCTAG

# Drug_Target_11_General_Function:
Involved in carbon-nitrogen ligase activity, with glutamine as amido-N-donor

# Drug_Target_11_General_References:
12597275	Kaneko T, Nakamura Y, Sato S, Minamisawa K, Uchiumi T, Sasamoto S, Watanabe A, Idesawa K, Iriguchi M, Kawashima K, Kohara M, Matsumoto M, Shimpo S, Tsuruoka H, Wada T, Yamada M, Tabata S: Complete genomic sequence of nitrogen-fixing symbiotic bacterium Bradyrhizobium japonicum USDA110. DNA Res. 2002 Dec 31;9(6):189-97.
12711609	Shin S, Yun YS, Koo HM, Kim YS, Choi KY, Oh BH: Characterization of a novel Ser-cisSer-Lys catalytic triad in comparison with the classical Ser-His-Asp triad. J Biol Chem. 2003 Jul 4;278(27):24937-43. Epub 2003 Apr 23.

# Drug_Target_11_HGNC_ID:
Not Available

# Drug_Target_11_HPRD_ID:
Not Available

# Drug_Target_11_ID:
4600

# Drug_Target_11_Locus:
Not Available

# Drug_Target_11_Molecular_Weight:
43682

# Drug_Target_11_Name:
Malonamidase E2

# Drug_Target_11_Number_of_Residues:
414

# Drug_Target_11_PDB_ID:
1OBL

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
PF01425	Amidase

# Drug_Target_11_Protein_Sequence:
>Malonamidase E2
MISLADLQRRIETGELSPNAAIAQSHAAIEAREKEVHAFVRHDKSARAQASGPLRGIAVG
IKDIIDTANMPTEMGSEIYRGWQPRSDAPVVMMLKRAGATIIGKTTTTAFASRDPTATLN
PHNTGHSPGGSSSGSAAAVGAGMIPLALGTQTGGSVIRPAAYCGTAAIKPSFRMLPTVGV
KCYSWALDTVGLFGARAEDLARGLLAMTGRSEFSGIVPAKAPRIGVVRQEFAGAVEPAAE
QGLQAAIKAAERAGASVQAIDLPEAVHEAWRIHPIIQDFEAHRALAWEFSEHHDEIAPML
RASLDATVGLTPKEYDEARRIGRRGRRELGEVFEGVDVLLTYSAPGTAPAKALASTGDPR
YNRLWTLMGNPCVNVPVLKVGGLPIGVQVIARFGNDAHALATAWFLEDALAKSG

# Drug_Target_11_Reaction:
Not Available

# Drug_Target_11_Signals:
None

# Drug_Target_11_Specific_Function:
Not Available

# Drug_Target_11_SwissProt_ID:
Q9ZIV5

# Drug_Target_11_SwissProt_Name:
Q9ZIV5_BRAJA

# Drug_Target_11_Synonyms:
Not Available

# Drug_Target_11_Theoretical_pI:
8.13

# Drug_Target_11_Transmembrane_Regions:
None

# Drug_Target_12_Cellular_Location:
Not Available

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
Not Available

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
Not Available

# Drug_Target_12_GenBank_ID_Gene:
AF290086

# Drug_Target_12_GenBank_ID_Protein:
Not Available

# Drug_Target_12_GeneCard_ID:
Not Available

# Drug_Target_12_Gene_Name:
mvaS

# Drug_Target_12_Gene_Sequence:
>1167 bp
TTACTCTGGTCTGTGATATTCGCGAACGTTATTTTCAATATTTGATAAGTAGAAAATATG
ACGATCTTCATGAACAGCATCTTGTTCTTCGTCAAATTCAACGTCATCAAAACGTTTGAA
GAATGTTTCATATGCATCAACAGATACTTCAGTACGGTTATTTAATAATGCTTTATGTGC
AGCTTGATCTAAATGATCTTTGTAGCCTACAACTAATGTCGCACTATAAAATTCAACAAC
TGAACCTGAGCCATAACTGAATAAACCGATTGTTTCACCAGCTTGTAAATCACGATTTTC
AAGTAATGATATTAGGCTTAAATATAATGATCCAGTATAAATATTACCGACATAACGGTT
ATAATCTACAGCATCTTCATATCCTGAACGTAAACGCTCTTGAGTTGTTTCATCAGCGTT
ATCAATGATTGACTCTAATGCCTTTTTACCCATTTTTGTAAATGGAACATGGAAGCATAG
AGATGCGAAGTCAGCTAGCGACTTACCTTGACGTTTTGCGTATTCATTCCAGCTTTGTTG
GAATGAGCGGATATAAGCATCTTTAGATAATGCACCATCAACTAATGGATATTTATGTCC
AGTTGGACGCCAGAAATCATAAACGTCTTCAGTGTAAGCAACAGCATCTTCATTTAATGC
CAAAATGCTTGGATTATGTGCAATAACCATCGCAACTGCGCCAGCACCTTGTGTTGGCTC
GCCGCCTGAATTCAATCCATAACGTGCTGTATCTGTAGCAATAACTAATACTTTTTCATT
CGGTCTAGTTGCTAAATAATCTTTAGCTAATTGAATTGCTGGTGTTGCAGCATAACAAGC
TTCTTTCATTTCAAAGCAACGTGCAAAAGGTTGAATACCTAATAAGTTGTGAATTTGAAC
AGCGGCTGCTTTAGCAGCATCAACTGCTGATTCAGTTGCCACAATTACCATACCAATTTT
CTTTTTATCTTCGTCTGTTATAATGTCCTTAGCAGCGTTAGCGCCCATTGAAACGATGTC
TTGGTTTACAGGACTAACAGCCATTTCAGTTTGACCAATTCCAATTAAAAATTTGTTTGG
GTCTACTTGGCGTGCTTCTGCTAATTTAGCCATGTCTACATAGTATTTTGGAACGTAAAA
GTTTATTTTGTCGATACCTATTGTCAT

# Drug_Target_12_General_Function:
Involved in hydroxymethylglutaryl-CoA synthase activity

# Drug_Target_12_General_References:
10894743	Wilding EI, Brown JR, Bryant AP, Chalker AF, Holmes DJ, Ingraham KA, Iordanescu S, So CY, Rosenberg M, Gwynn MN: Identification, evolution, and essentiality of the mevalonate pathway for isopentenyl diphosphate biosynthesis in gram-positive cocci. J Bacteriol. 2000 Aug;182(15):4319-27.

# Drug_Target_12_HGNC_ID:
Not Available

# Drug_Target_12_HPRD_ID:
Not Available

# Drug_Target_12_ID:
4601

# Drug_Target_12_Locus:
Not Available

# Drug_Target_12_Molecular_Weight:
43218

# Drug_Target_12_Name:
HMG-CoA synthase

# Drug_Target_12_Number_of_Residues:
388

# Drug_Target_12_PDB_ID:
1XPK

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF01154	HMG_CoA_synt_N
PF08540	HMG_CoA_synt_C

# Drug_Target_12_Protein_Sequence:
>HMG-CoA synthase
MTIGIDKINFYVPKYYVDMAKLAEARQVDPNKFLIGIGQTEMAVSPVNQDIVSMGANAAK
DIITDEDKKKIGMVIVATESAVDAAKAAAVQIHNLLGIQPFARCFEMKEACYAATPAIQL
AKDYLATRPNEKVLVIATDTARYGLNSGGEPTQGAGAVAMVIAHNPSILALNEDAVAYTE
DVYDFWRPTGHKYPLVDGALSKDAYIRSFQQSWNEYAKRQGKSLADFASLCFHVPFTKMG
KKALESIIDNADETTQERLRSGYEDAVDYNRYVGNIYTGSLYLSLISLLENRDLQAGETI
GLFSYGSGSVVEFYSATLVVGYKDHLDQAAHKALLNNRTEVSVDAYETFFKRFDDVEFDE
EQDAVHEDRHIFYLSNIENNVREYHRPE

# Drug_Target_12_Reaction:
Not Available

# Drug_Target_12_Signals:
None

# Drug_Target_12_Specific_Function:
Not Available

# Drug_Target_12_SwissProt_ID:
Q9FD87

# Drug_Target_12_SwissProt_Name:
Q9FD87_STAAU

# Drug_Target_12_Synonyms:
Not Available

# Drug_Target_12_Theoretical_pI:
4.72

# Drug_Target_12_Transmembrane_Regions:
None

# Drug_Target_13_Cellular_Location:
Not Available

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
Not Available

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
Not Available

# Drug_Target_13_GenBank_ID_Gene:
Not Available

# Drug_Target_13_GenBank_ID_Protein:
Not Available

# Drug_Target_13_GeneCard_ID:
Not Available

# Drug_Target_13_Gene_Name:
tthHB8IM

# Drug_Target_13_Gene_Sequence:
Not Available

# Drug_Target_13_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_13_General_References:
Not Available

# Drug_Target_13_HGNC_ID:
Not Available

# Drug_Target_13_HPRD_ID:
Not Available

# Drug_Target_13_ID:
4602

# Drug_Target_13_Locus:
Not Available

# Drug_Target_13_Molecular_Weight:
15219

# Drug_Target_13_Name:
Osmotically inducible protein C

# Drug_Target_13_Number_of_Residues:
142

# Drug_Target_13_PDB_ID:
1UKK

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF02566	OsmC

# Drug_Target_13_Protein_Sequence:
>Osmotically inducible protein C
MPVRKAKAVWEGGLRQGKGVMELQSQAFQGPYSYPSRFEEGEGTNPEELIAAAHAGXFSM
ALAASLEREGFPPKRVSTEARVHLEVVDGKPTLTRIELLTEAEVPGISSEKFLEIAEAAK
EGCPVSRALAGVKEVVLTARLV

# Drug_Target_13_Reaction:
Not Available

# Drug_Target_13_Signals:
None

# Drug_Target_13_Specific_Function:
Not Available

# Drug_Target_13_SwissProt_ID:
P84124

# Drug_Target_13_SwissProt_Name:
P84124_THETH

# Drug_Target_13_Synonyms:
Not Available

# Drug_Target_13_Theoretical_pI:
5.32

# Drug_Target_13_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
U00096

# Drug_Target_1_GenBank_ID_Protein:
1787924

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
pdxY

# Drug_Target_1_Gene_Sequence:
>864 bp
TCAGAGCTTTGTTGCGCTGAAGTAATGTTCTGGTTTGGCAATACGATCCTGAGCAGCCAC
CACTTGCAGCTCATATTCCTGCATTGCTTTGGTGGTCACCATGATTTCGTAGACTGCAGC
GGTCACATGTTCCAGCGCCTCCTGCAGCGTTGCCCCCTGAAGCAGTTTCACCAGCAGTAA
ACCGCTCGTCACATCACCAACACCTACCGGCTGGCGCATACCAAAATCCACCAGCGGACG
GCTGATATGCCAGGCTTCATCGGCGGTGACCAGCAGCATTTCAAAACGGTCACGGCTGTA
GCCAGCTCGCGCCAGGTGTTTAACCAACACAATTTGTGGCCCTTGCGCAATGAGTTCGCG
CGCTGCCAGAACCGCTTCTTCGACGTTATTTACCGCATGCTCACAGAGTATTTCCAGCTC
AACCAGATTTGGCGCAATGATATCGCTGGCAGGCAAACCGTGCCGCACATGAAACTCTGC
GACACCCGGTGCAACGATACAGCCTTTTTCCGGATGACCCATTACCGGATCGCAAAAATA
TTTCGCCTGCGGATTCGCGGCTTTCACCTGACGGACGATACCGAGGATATGTTCACCCTG
CTCCGCCGATCCCAGATAGCCACTTAATACGGCATCACAGGTGTGTAATTTATCAATGGC
GGCAATGCCTTGCACAATTTCGGTTAAATGGCTGGGCGGCATCACGCAGCCAGTCCATTT
GCCGTATTGGGTGTGATTAGAAAATTGAACGGTGTTCAGCGGCCAGACGTTCGCGCCCAG
GCGGCGCATCGGAAACTCTGCCGCACTGTTACCCGCATGACCATAAACAACGTGAGACTG
GATAGCGAGAATATTTTTCATCAT

# Drug_Target_1_General_Function:
Coenzyme transport and metabolism

# Drug_Target_1_General_References:
9097039	Aiba H, Baba T, Hayashi K, Inada T, Isono K, Itoh T, Kasai H, Kashimoto K, Kimura S, Kitakawa M, Kitagawa M, Makino K, Miki T, Mizobuchi K, Mori H, Mori T, Motomura K, Nakade S, Nakamura Y, Nashimoto H, Nishio Y, Oshima T, Saito N, Sampei G, Horiuchi T, et al.: A 570-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 28.0-40.1 min region on the linkage map. DNA Res. 1996 Dec 31;3(6):363-77.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9537380	Yang Y, Tsui HC, Man TK, Winkler ME: Identification and function of the pdxY gene, which encodes a novel pyridoxal kinase involved in the salvage pathway of pyridoxal 5'-phosphate biosynthesis in Escherichia coli K-12. J Bacteriol. 1998 Apr;180(7):1814-21.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2670

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
31191

# Drug_Target_1_Name:
Pyridoxamine kinase

# Drug_Target_1_Number_of_Residues:
286

# Drug_Target_1_PDB_ID:
1TD2

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00294	PfkB

# Drug_Target_1_Protein_Sequence:
>Pyridoxamine kinase
MKNILAIQSHVVYGHAGNSAAEFPMRRLGANVWPLNTVQFSNHTQYGKWTGCVMPPSHLT
EIVQGIAAIDKLHTCDAVLSGYLGSAEQGEHILGIVRQVKAANPQAKYFCDPVMGHPEKG
CIVAPGVAEFHVRHGLPASDIIAPNLVELEILCEHAVNNVEEAVLAARELIAQGPQIVLV
KHLARAGYSRDRFEMLLVTADEAWHISRPLVDFGMRQPVGVGDVTSGLLLVKLLQGATLQ
EALEHVTAAVYEIMVTTKAMQEYELQVVAAQDRIAKPEHYFSATKL

# Drug_Target_1_Reaction:
ATP + pyridoxal = ADP + pyridoxal 5'-phosphate

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Phosphorylates B6 vitamers; functions in a salvage pathway. Uses pyridoxamine, but has negligible activity toward pyridoxal and pyridoxine as substrates

# Drug_Target_1_SwissProt_ID:
P77150

# Drug_Target_1_SwissProt_Name:
PDXY_ECOLI

# Drug_Target_1_Synonyms:
EC 2.7.1.35
PM kinase

# Drug_Target_1_Theoretical_pI:
6.50

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasmic

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
M11189

# Drug_Target_2_GenBank_ID_Protein:
142604

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
blm

# Drug_Target_2_Gene_Sequence:
>774 bp
ATGAAAAAGAATACGTTGTTAAAAGTAGGATTATGTGTAGGTTTACTAGGAACAATTCAA
TTTGTTAGCACAATTTCTTCTGTACAAGCATCACAAAAGGTAGAGAAAACAGTAATAAAA
AATGAGACGGGAACCATTTCAATATCTCAGTTAAACAAGAATGTATGGGTTCATACGGAG
TTAGGTTCTTTTAATGGAGAAGCAGTTCCTTCGAACGGTCTAGTTCTTAATACTTCTAAA
GGGTTAGTACTTGTGGATTCTTCTTGGGATGACAAATTAACGAAGGAACTAATAGAAATG
GTAGAAAAGAAATTTCAGAAGCGCGTAACGGATGTCATTATTACACATGCGCACGCTGAT
CGAATTGGCGGAATAAAAACGTTGAAAGAAAGAGGCATTAAAGCGCATAGTACAGCATTA
ACTGCAGAACTAGCAAAGAAAAATGGATATGAAGAACCGCTTGGAGATTTACAAACCGTT
ACAAATTTGAAGTTTGGAAATATGAAAGTAGAAACATTTTATCCAGGGAAAGGGCATACA
GAAGATAATATTGTCGTATGGTTACCGCAATACAATATTTTAGTTGGAGGCTGTTTAGTG
AAATCTACGTCCGCGAAAGATTTAGGAAACGTTGCGGATGCTTATGTAAATGAATGGTCT
ACATCGATTGAGAATGTGCTGAAGCGATATAGAAATATAAATGCAGTAGTGCCTGGTCAT
GGGGAAGTAGGGGACAAAGGATTACTTTTACATACATTGGATTTATTAAAATAA

# Drug_Target_2_General_Function:
Involved in zinc ion binding

# Drug_Target_2_General_References:
10933508	Chantalat L, Duee E, Galleni M, Frere JM, Dideberg O: Structural effects of the active site mutation cysteine to serine in Bacillus cereus zinc-beta-lactamase. Protein Sci. 2000 Jul;9(7):1402-6.
3124808	Sutton BJ, Artymiuk PJ, Cordero-Borboa AE, Little C, Phillips DC, Waley SG: An X-ray-crystallographic study of beta-lactamase II from Bacillus cereus at 0.35 nm resolution. Biochem J. 1987 Nov 15;248(1):181-8.
3930290	Ambler RP, Daniel M, Fleming J, Hermoso JM, Pang C, Waley SG: The amino acid sequence of the zinc-requiring beta-lactamase II from the bacterium Bacillus cereus 569. FEBS Lett. 1985 Sep 23;189(2):207-11.
3930467	Hussain M, Carlino A, Madonna MJ, Lampen JO: Cloning and sequencing of the metallothioprotein beta-lactamase II gene of Bacillus cereus 569/H in Escherichia coli. J Bacteriol. 1985 Oct;164(1):223-9.
7588620	Carfi A, Pares S, Duee E, Galleni M, Duez C, Frere JM, Dideberg O: The 3-D structure of a zinc metallo-beta-lactamase from Bacillus cereus reveals a new type of protein fold. EMBO J. 1995 Oct 16;14(20):4914-21.
9730812	Fabiane SM, Sohi MK, Wan T, Payne DJ, Bateson JH, Mitchell T, Sutton BJ: Crystal structure of the zinc-dependent beta-lactamase from Bacillus cereus at 1.9 A resolution: binuclear active site with features of a mononuclear enzyme. Biochemistry. 1998 Sep 8;37(36):12404-11.
9761898	Carfi A, Duee E, Galleni M, Frere JM, Dideberg O: 1.85 A resolution structure of the zinc (II) beta-lactamase from Bacillus cereus. Acta Crystallogr D Biol Crystallogr. 1998 May 1;54(Pt 3):313-23.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2603

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
28093

# Drug_Target_2_Name:
Beta-lactamase II

# Drug_Target_2_Number_of_Residues:
257

# Drug_Target_2_PDB_ID:
1MQO

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00753	Lactamase_B

# Drug_Target_2_Protein_Sequence:
>Beta-lactamase II precursor
MKKNTLLKVGLCVGLLGTIQFVSTISSVQASQKVEKTVIKNETGTISISQLNKNVWVHTE
LGSFNGEAVPSNGLVLNTSKGLVLVDSSWDDKLTKELIEMVEKKFQKRVTDVIITHAHAD
RIGGIKTLKERGIKAHSTALTAELAKKNGYEEPLGDLQTVTNLKFGNMKVETFYPGKGHT
EDNIVVWLPQYNILVGGCLVKSTSAKDLGNVADAYVNEWSTSIENVLKRYRNINAVVPGH
GEVGDKGLLLHTLDLLK

# Drug_Target_2_Reaction:
a beta-lactam + H2O = a substituted beta-amino acid

# Drug_Target_2_Signals:
1-30

# Drug_Target_2_Specific_Function:
Can hydrolyze carbapenem compounds

# Drug_Target_2_SwissProt_ID:
P04190

# Drug_Target_2_SwissProt_Name:
BLA2_BACCE

# Drug_Target_2_Synonyms:
Beta-lactamase II precursor
Cephalosporinase
EC 3.5.2.6
Penicillinase

# Drug_Target_2_Theoretical_pI:
9.29

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
Not Available

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
PAPOLA

# Drug_Target_3_Gene_Sequence:
Not Available

# Drug_Target_3_General_Function:
Not Available

# Drug_Target_3_General_References:
Not Available

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
7025

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
Not Available

# Drug_Target_3_Name:
Poly(A) polymerase alpha

# Drug_Target_3_Number_of_Residues:
0

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
Not Available

# Drug_Target_3_Protein_Sequence:
Not Available

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
Not Available

# Drug_Target_3_Specific_Function:
Not Available

# Drug_Target_3_SwissProt_ID:
P51003

# Drug_Target_3_SwissProt_Name:
PAPOA_HUMAN

# Drug_Target_3_Synonyms:
Not Available

# Drug_Target_3_Theoretical_pI:
Not Available

# Drug_Target_3_Transmembrane_Regions:
Not Available

# Drug_Target_4_Cellular_Location:
Cytoplasm

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
M32278

# Drug_Target_4_GenBank_ID_Protein:
142536

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
aroH

# Drug_Target_4_Gene_Sequence:
>384 bp
ATGATGATTCGCGGAATTCGCGGAGCAACTACAGTTGAACGGGATACTGAAGAAGAAATT
TTACAAAAAACTAAACAGCTGTTAGAGAAAATCATAGAAGAAAATCATACAAAACCGGAA
GATGTTGTTCAAATGCTTCTGTCGGCTACACCTGATTTGCACGCTGTTTTCCCGGCAAAA
GCTGTTCGCGAGCTTTCAGGATGGCAGTATGTACCGGTAACATGTATGCAGGAAATGGAC
GTAACAGGCGGTCTGAAAAAGTGCATAAGAGTCATGATGACGGTCCAGACAGATGTCCCT
CAGGATCAGATCAGACATGTATATTTAGAAAAAGCTGTCGTATTGAGGCCCGATTTATCA
TTGACAAAAAATACTGAATTGTAA

# Drug_Target_4_General_Function:
Involved in chorismate mutase activity

# Drug_Target_4_General_References:
10818343	Ladner JE, Reddy P, Davis A, Tordova M, Howard AJ, Gilliland GL: The 1.30 A resolution structure of the Bacillus subtilis chorismate mutase catalytic homotrimer. Acta Crystallogr D Biol Crystallogr. 2000 Jun;56(Pt 6):673-83.
2105742	Gray JV, Golinelli-Pimpaneau B, Knowles JR: Monofunctional chorismate mutase from Bacillus subtilis: purification of the protein, molecular cloning of the gene, and overexpression of the gene product in Escherichia coli. Biochemistry. 1990 Jan 16;29(2):376-83.
8046752	Chook YM, Gray JV, Ke H, Lipscomb WN: The monofunctional chorismate mutase from Bacillus subtilis. Structure determination of chorismate mutase and its complexes with a transition state analog and prephenate, and implications for the mechanism of the enzymatic reaction. J Mol Biol. 1994 Jul 29;240(5):476-500.
8378335	Chook YM, Ke H, Lipscomb WN: Crystal structures of the monofunctional chorismate mutase from Bacillus subtilis and its complex with a transition state analog. Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8600-3.
8471608	Rajagopalan JS, Taylor KM, Jaffe EK: 13C NMR studies of the enzyme-product complex of Bacillus subtilis chorismate mutase. Biochemistry. 1993 Apr 20;32(15):3965-72.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
2714

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
14517

# Drug_Target_4_Name:
Chorismate mutase

# Drug_Target_4_Number_of_Residues:
127

# Drug_Target_4_PDB_ID:
1DBF

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF07736	CM_1

# Drug_Target_4_Protein_Sequence:
>Chorismate mutase
MMIRGIRGATTVERDTEEEILQKTKQLLEKIIEENHTKPEDVVQMLLSATPDLHAVFPAK
AVRELSGWQYVPVTCMQEMDVTGGLKKCIRVMMTVQTDVPQDQIRHVYLEKVVVLRPDLS
LTKNTEL

# Drug_Target_4_Reaction:
chorismate = prephenate

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Chorismate = prephenate

# Drug_Target_4_SwissProt_ID:
P19080

# Drug_Target_4_SwissProt_Name:
CHMU_BACSU

# Drug_Target_4_Synonyms:
CM
EC 5.4.99.5

# Drug_Target_4_Theoretical_pI:
5.70

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Mitochondrion. Cytoplasm

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
GSR

# Drug_Target_5_GenBank_ID_Gene:
X15722

# Drug_Target_5_GenBank_ID_Protein:
31825

# Drug_Target_5_GeneCard_ID:
GSR

# Drug_Target_5_Gene_Name:
GSR

# Drug_Target_5_Gene_Sequence:
>1569 bp
ATGGCCCTGCTGCCCCGAGCCCTGAGCGCCGGCGCGGGACCGAGCTGGCGGCGGGCGGCG
CGCGCCTTCCGAGGCTTCCTGCTGCTTCTGCCCGAGCCCGCGGCCCTCACGCGCGCCCTC
TCCCGTGCCATGGCCTGCAGGCAGGAGCCGCAGCCGCAGGGCCCGCCGCCCGCTGCTGGC
GCCGTGGCCTCCTATGACTACCTGGTGATCGGGGGCGGCTCGGGCGGGCTGGCCAGCGCG
CGCAGGGCGGCCGAGCTGGGTGCCAGGGCCGCCGTGGTGGAGAGCCACAAGCTGGGTGGC
ACTTGCGTGAATGTTGGATGTGTACCCAAAAAGGTAATGTGGAACACAGCTGTCCACTCT
GAATTCATGCATGATCATGCTGATTATGGCTTTCCAAGTTGTGAGGGTAAATTCAATTGG
CGTGTTATTAAGGAAAAGCGGGATGCCTATGTGAGCCGCCTGAATGCCATCTATCAAAAC
AATCTCACCAAGTCCCATATAGAAATCATCCGTGGCCATGCAGCCTTCACGAGTGATCCC
AAGCCCACAATAGAGGTCAGTGGGAAAAAGTACACCGCCCCACACATCCTGATCGCCACA
GGTGGTATGCCCTCCACCCCTCATGAGAGCCAGATCCCCGGTGCCAGCTTAGGAATAACC
AGCGATGGATTTTTTCAGCTGGAAGAATTGCCCGGCCGCAGCGTCATTGTTGGTGCAGGT
TACATTGCTGTGGAGATGGCAGGGATCCTGTCAGCCCTGGGTTCTAAGACATCACTGATG
ATACGGCATGATAAGGTACTTAGAAGTTTTGATTCAATGATCAGCACCAACTGCACGGAG
GAGCTGGAGAACGCTGGCGTGGAGGTGCTGAAGTTCTCCCAGGTCAAGGAGGTTAAAAAG
ACTTTGTCGGGCTTGGAAGTCAGCATGGTTACTGCAGTTCCCGGTAGGCTACCAGTCATG
ACCATGATTCCAGATGTTGACTGCCTGCTCTGGGCCATTGGGCGGGTCCCGAATACCAAG
GACCTGAGTTTAAACAAACTGGGGATTCAAACCGATGACAAGGGTCATATCATCGTAGAC
GAATTCCAGAATACCAACGTCAAAGGCATCTATGCAGTTGGGGATGTATGTGGAAAAGCT
CTTCTTACTCCAGTTGCAATAGCTGCTGGCCGAAAACTTGCCCATCGACTTTTTGAATAT
AAGGAAGATTCCAAATTAGATTATAACAACATCCCAACTGTGGTCTTCAGCCACCCCCCT
ATTGGGACAGTGGGACTCACGGAAGATGAAGCCATTCATAAATATGGAATAGAAAATGTG
AAGACCTATTCAACGAGCTTTACCCCGATGTATCACGCAGTTACCAAAAGGAAAACAAAA
TGTGTGATGAAAATGGTCTGTGCTAACAAGGAAGAAAAGGTGGTTGGGATCCATATGCAG
GGACTTGGGTGTGATGAAATGCTGCAGGGTTTTGCTGTTGCAGTGAAGATGGGAGCAACG
AAGGCAGACTTTGACAACACAGTCGCCATTCACCCTACCTCTTCAGAAGAGCTGGTCACA
CTTCGTTGA

# Drug_Target_5_General_Function:
RNA processing and modification

# Drug_Target_5_General_References:
10708558	Kelner MJ, Montoya MA: Structural organization of the human glutathione reductase gene: determination of correct cDNA sequence and identification of a mitochondrial leader sequence. Biochem Biophys Res Commun. 2000 Mar 16;269(2):366-8.
2185014	Tutic M, Lu XA, Schirmer RH, Werner D: Cloning and sequencing of mammalian glutathione reductase cDNA. Eur J Biochem. 1990 Mar 30;188(3):523-8.
3656429	Karplus PA, Schulz GE: Refined structure of glutathione reductase at 1.54 A resolution. J Mol Biol. 1987 Jun 5;195(3):701-29.
7060551	Krauth-Siegel RL, Blatterspiel R, Saleh M, Schiltz E, Schirmer RH, Untucht-Grau R: Glutathione reductase from human erythrocytes. The sequences of the NADPH domain and of the interface domain. Eur J Biochem. 1982 Jan;121(2):259-67.
7334521	Thieme R, Pai EF, Schirmer RH, Schulz GE: Three-dimensional structure of glutathione reductase at 2 A resolution. J Mol Biol. 1981 Nov 15;152(4):763-82.
8626496	Savvides SN, Karplus PA: Kinetics and crystallographic analysis of human glutathione reductase in complex with a xanthene inhibitor. J Biol Chem. 1996 Apr 5;271(14):8101-7.
9174360	Stoll VS, Simpson SJ, Krauth-Siegel RL, Walsh CT, Pai EF: Glutathione reductase turned into trypanothione reductase: structural analysis of an engineered change in substrate specificity. Biochemistry. 1997 May 27;36(21):6437-47.
923580	Krohne-Ehrich G, Schirmer RH, Untucht-Grau R: Glutathione reductase from human erythrocytes. Isolation of the enzyme and sequence analysis of the redox-active peptide. Eur J Biochem. 1977 Oct 17;80(1):65-71.
9546215	Becker K, Savvides SN, Keese M, Schirmer RH, Karplus PA: Enzyme inactivation through sulfhydryl oxidation by physiologic NO-carriers. Nat Struct Biol. 1998 Apr;5(4):267-71.

# Drug_Target_5_HGNC_ID:
HGNC:4623

# Drug_Target_5_HPRD_ID:
00704

# Drug_Target_5_ID:
714

# Drug_Target_5_Locus:
8p21.1

# Drug_Target_5_Molecular_Weight:
56258

# Drug_Target_5_Name:
Glutathione reductase, mitochondrial

# Drug_Target_5_Number_of_Residues:
522

# Drug_Target_5_PDB_ID:
1BWC

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00070	Pyr_redox
PF02852	Pyr_redox_dim
PF07992	Pyr_redox_2

# Drug_Target_5_Protein_Sequence:
>Glutathione reductase, mitochondrial precursor
MALLPRALSAGAGPSWRRAARAFRGFLLLLPEPAALTRALSRAMACRQEPQPQGPPPAAG
AVASYDYLVIGGGSGGLASARRAAELGARAAVVESHKLGGTCVNVGCVPKKVMWNTAVHS
EFMHDHADYGFPSCEGKFNWRVIKEKRDAYVSRLNAIYQNNLTKSHIEIIRGHAAFTSDP
KPTIEVSGKKYTAPHILIATGGMPSTPHESQIPGASLGITSDGFFQLEELPGRSVIVGAG
YIAVEMAGILSALGSKTSLMIRHDKVLRSFDSMISTNCTEELENAGVEVLKFSQVKEVKK
TLSGLEVSMVTAVPGRLPVMTMIPDVDCLLWAIGRVPNTKDLSLNKLGIQTDDKGHIIVD
EFQNTNVKGIYAVGDVCGKALLTPVAIAAGRKLAHRLFEYKEDSKLDYNNIPTVVFSHPP
IGTVGLTEDEAIHKYGIENVKTYSTSFTPMYHAVTKRKTKCVMKMVCANKEEKVVGIHMQ
GLGCDEMLQGFAVAVKMGATKADFDNTVAIHPTSSEELVTLR

# Drug_Target_5_Reaction:
2 glutathione + NADP+ = glutathione disulfide + NADPH + H+

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Maintains high levels of reduced glutathione in the cytosol

# Drug_Target_5_SwissProt_ID:
P00390

# Drug_Target_5_SwissProt_Name:
GSHR_HUMAN

# Drug_Target_5_Synonyms:
EC 1.8.1.7
GR
GRase
Glutathione reductase, mitochondrial precursor

# Drug_Target_5_Theoretical_pI:
8.66

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Not Available

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
AE000513

# Drug_Target_6_GenBank_ID_Protein:
6460202

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
luxS

# Drug_Target_6_Gene_Sequence:
>477 bp
TCAGCGTTCGAGCAGAATGGTTTCCTGAACTTTCAGCCCCTGGTCGAGCACGTCGCGGGC
GTGCTGGCGGGCGGCGGCGAGGTCGTGGTCGCGGTAGTTGCCGCATTCGAGTTCGCTCAC
GCCGGGAATGGGTTGGTCGTGCCCGGCGGTGTCCTTGAGGGCCGCCTCGAAGGCTTTCAT
CACGCCCTGCTCGTCGGGTTCACCGATGACGGCCATGTACATGCCGGTGCGGCAGCCCAT
CGGGGACACGTCCACCACGCCCTCGAGGTGGTCGCGCATGTAGCCCGCCAGCAGGTGCTC
GAGCGTGTGAATGGCGGCGGGGTCGATGGCGCCCTGGTTGGGCTGCAAGAAGCGCAGGTC
GTACTTGGAGATCTGGTCACCCTTCGGGGTGGTCTTGACCCCGGCGAGGCGGACATAGGG
AGCCTTGACCTTGGTGTGGTCCAGATCGAACGATTCGACGTTTGCCATGTCGGGCAT

# Drug_Target_6_General_Function:
Signal transduction mechanisms

# Drug_Target_6_General_References:
10567266	White O, Eisen JA, Heidelberg JF, Hickey EK, Peterson JD, Dodson RJ, Haft DH, Gwinn ML, Nelson WC, Richardson DL, Moffat KS, Qin H, Jiang L, Pamphile W, Crosby M, Shen M, Vamathevan JJ, Lam P, McDonald L, Utterback T, Zalewski C, Makarova KS, Aravind L, Daly MJ, Minton KW, Fleischmann RD, Ketchum KA, Nelson KE, Salzberg S, Smith HO, Venter JC, Fraser CM: Genome sequence of the radioresistant bacterium Deinococcus radiodurans R1. Science. 1999 Nov 19;286(5444):1571-7.
11435117	Lewis HA, Furlong EB, Laubert B, Eroshkina GA, Batiyenko Y, Adams JM, Bergseid MG, Marsh CD, Peat TS, Sanderson WE, Sauder JM, Buchanan SG: A structural genomics approach to the study of quorum sensing: crystal structures of three LuxS orthologs. Structure. 2001 Jun;9(6):527-37.

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
2664

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
17395

# Drug_Target_6_Name:
S-ribosylhomocysteine lyase

# Drug_Target_6_Number_of_Residues:
158

# Drug_Target_6_PDB_ID:
1VH2

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF02664	LuxS

# Drug_Target_6_Protein_Sequence:
>S-ribosylhomocysteine lyase
MPDMANVESFDLDHTKVKAPYVRLAGVKTTPKGDQISKYDLRFLQPNQGAIDPAAIHTLE
HLLAGYMRDHLEGVVDVSPMGCRTGMYMAVIGEPDEQGVMKAFEAALKDTAGHDQPIPGV
SELECGNYRDHDLAAARQHARDVLDQGLKVQETILLER

# Drug_Target_6_Reaction:
S-(5-deoxy-D-ribos-5-yl)-L-homocysteine = L-homocysteine + (4S)-4,5-dihydroxypentan-2,3-dione

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Involved in the synthesis of autoinducer 2 (AI-2) which is secreted by bacteria and is used to communicate both the cell density and the metabolic potential of the environment. The regulation of gene expression in response to changes in cell density is called quorum sensing. Catalyzes the transformation of S-ribosylhomocysteine (RHC) to homocysteine (HC) and 4,5- dihydroxy-2,3-pentadione (DPD)

# Drug_Target_6_SwissProt_ID:
Q9RRU8

# Drug_Target_6_SwissProt_Name:
LUXS_DEIRA

# Drug_Target_6_Synonyms:
AI-2 synthesis protein
Autoinducer-2 production protein luxS
EC 4.4.1.21

# Drug_Target_6_Theoretical_pI:
5.01

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Cytoplasmic

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
M15201

# Drug_Target_7_GenBank_ID_Protein:
151137

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
clcD

# Drug_Target_7_Gene_Sequence:
>711 bp
ATGTTGACTGAAGGGATATCGATTCAATCGTATGACGGGCATACATTCGGCGCGCTCGTG
GGCTCGCCGGCCAAAGCGCCCGCTCCCGTGATTGTGATCGCTCAAGAAATATTTGGTGTG
AACGCGTTCATGCGAGAAACGGTGTCATGGCTGGTCGACCAGGGGTATGCGGCAGTTTGC
CCTGATCTGTACGCGCGCCAGGCGCCAGGTACAGCACTCGATCCGCAGGATGAGCGCCAG
AGAGAGCAAGCCTACAAGCTCTGGCAGGCCTTCGACATGGAGGCCGGCGTGGGCGATCTG
GAGGCTGCTATCCGCTATGCGCGACACCAACCCTACAGCAACGGCAAGGTGGGATTGGTG
GGGTATTGCCTGGGCGGTGCGCTTGCCTTTCTAGTGGCCGCCAAAGGATACGTGGATCGC
GCCGTAGGCTACTACGGTGTTGGACTGGAGAAGCAGCTCAAGAAGGTCCCGGAAGTCAAG
CATCCGGCGTTGTTTCACATGGGCGGCCAAGACCACTTCGTGCCCGCGCCAAGCCGCCAG
CTGATTACTGAAGGCTTCGGTGCCAATCCATTGCTGCAAGTGCACTGGTACGAAGAGGCC
GGACACTCGTTCGCCAGGACGAGCAGTTCGGGCTATGTGGCGAGTGCCGCGGCGTTGGCC
AACGAACGTAGACTGGATTTCCTGGCGCCCTTGCAGAGCAAGAAGCCATGA

# Drug_Target_7_General_Function:
Secondary metabolites biosynthesis, transport and catabolism

# Drug_Target_7_General_References:
2380986	Pathak D, Ollis D: Refined structure of dienelactone hydrolase at 1.8 A. J Mol Biol. 1990 Jul 20;214(2):497-525.
3221394	Pathak D, Ngai KL, Ollis D: X-ray crystallographic structure of dienelactone hydrolase at 2.8 A. J Mol Biol. 1988 Nov 20;204(2):435-45.
3804974	Frantz B, Ngai KL, Chatterjee DK, Ornston LN, Chakrabarty AM: Nucleotide sequence and expression of clcD, a plasmid-borne dienelactone hydrolase gene from Pseudomonas sp. strain B13. J Bacteriol. 1987 Feb;169(2):704-9.
9171435	Kasberg T, Seibert V, Schlomann M, Reineke W: Cloning, characterization, and sequence analysis of the clcE gene encoding the maleylacetate reductase of Pseudomonas sp. strain B13. J Bacteriol. 1997 Jun;179(11):3801-3.

# Drug_Target_7_HGNC_ID:
Not Available

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
2378

# Drug_Target_7_Locus:
Not Available

# Drug_Target_7_Molecular_Weight:
25555

# Drug_Target_7_Name:
Carboxymethylenebutenolidase

# Drug_Target_7_Number_of_Residues:
236

# Drug_Target_7_PDB_ID:
1DIN

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF01738	DLH

# Drug_Target_7_Protein_Sequence:
>Carboxymethylenebutenolidase
MLTEGISIQSYDGHTFGALVGSPAKAPAPVIVIAQEIFGVNAFMRETVSWLVDQGYAAVC
PDLYARQAPGTALDPQDERQREQAYKLWQAFDMEAGVGDLEAAIRYARHQPYSNGKVGLV
GYCLGGALAFLVAAKGYVDRAVGYYGVGLEKQLKKVPEVKHPALFHMGGQDHFVPAPSRQ
LITEGFGANPLLQVHWYEEAGHSFARTSSSGYVASAAALANERRLDFLAPLQSKKP

# Drug_Target_7_Reaction:
4-carboxymethylenebut-2-en-4-olide + H2O = 4-oxohex-2-enedioate

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Ring cleavage of cyclic ester dienelactone to produce maleylacetate

# Drug_Target_7_SwissProt_ID:
P0A115

# Drug_Target_7_SwissProt_Name:
CLCD_PSESB

# Drug_Target_7_Synonyms:
DLH
Dienelactone hydrolase
EC 3.1.1.45

# Drug_Target_7_Theoretical_pI:
6.88

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Periplasm

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
Not Available

# Drug_Target_8_GenBank_ID_Gene:
L46851

# Drug_Target_8_GenBank_ID_Protein:
1161236

# Drug_Target_8_GeneCard_ID:
Not Available

# Drug_Target_8_Gene_Name:
dmsA

# Drug_Target_8_Gene_Sequence:
>2469 bp
ATGACGAAGTTGTCAGGTCAGGAGCTGCATGCCGAACTCTCGCGGCGCGCCTTCCTGAGC
TATACGGCGGCGGTGGGGGCTCTCGGTCTCTGCGGCACCTCGCTCCTCGCGCAGGGGGCC
CGCGCGGAAGGTCTCGCCAATGGCGAGGTCATGTCGGGCTGCCACTGGGGCGTGTTCAAG
GCCCGGGTCGAGAACGGCCGCGCCGTGGCCTTCGAGCCCTGGGACAAGGATCCCGCGCCG
TCGCACCAGCTGCCGGGCGTGCTCGATTCGATCTATTCGCCCACGCGGATCAAATATCCG
ATGGTGCGCCGCGAGTTCCTCGAGAAGGGCGTGAACGCCGATCGCTCGACCCGCGGCAAC
GGCGATTTCGTCCGCGTCACCTGGGATGAGGCGCTCGACCTCGTGGCCCGCGAGCTGAAG
CGCGTTCAGGAGAGCTACGGCCCCACCGGCACCTTCGGCGGCTCCTACGGCTGGAAGAGC
CCGGGCCGGCTGCACAATTGTCAGGTCCTCATGCGCCGCGCGCTGAATCTGGCGGGCGGG
TTCGTGAACTCGTCGGGCGACTATTCGACGGCGGCCGCGCAGATCATCATGCCGCATGTC
ATGGGCACGCTCGAGGTCTACGAGCAGCAGACCGCCTGGCCCGTGGTGGTGGAGAACACC
GATCTTATGGTCTTCTGGGCCGCCGACCCGATGAAGACCAACGAGATCGGCTGGGTGATC
CCCGACCATGGCGCCTATGCCGGCATGAAGGCCCTGAAGGAGAAGGGCACCAGGGTCATC
TGCATCAACCCCGTGCGCACCGAGACGGCCGACTATTTCGGCGCCGACGTCGTGTCGCCC
CGGCCGCAGACCGACGTGGCGCTGATGCTCGGCATGGCGCACACGCTCTACAGCGAAGAC
CTGCACGACAAGGACTTCCTCGAGAACTGCACCACGGGCTTCGACCTCTTCGCGGCCTAC
CTGACCGGCGAGAGCGACGGCACGCCCAAGACGGCCGAATGGGCCGCCGAGATCTGCGGC
CTGCCGGCCGAGCAGATCAGGGAGCTCGCCCGCAGCTTCGTGGCCGGCCGGACGATGCTC
GCCGCGGGCTGGTCGATCCAGCGGATGCACCATGGCGAACAGGCGCACTGGATGCTCGTG
ACTCTGGCCTCGATGATCGGCCAGATCGGTCTGCCGGGCGGCGGCTTCGGCCTCAGCTAC
CACTATTCGAACGGCGGCTCGCCCACGAGCGACGGCCCGGCGCTGGGCGGGATCTCGGAC
GGCGGCAAGGCGGTCGAAGGCGCGGCCTGGCTGTCGGAGAGCGGCGCGACCTCGATCCCC
TGCGCCCGCGTGGTAGACATGCTGCTCAATCCGGGCGGCGAGTTCCAGTTCAACGGCGCC
ACGGCGACCTATCCCGACGTGAAGCTGGCCTACTGGGCGGGCGGCAACCCCTTCGCGCAC
CACCAGGACCGCAACCGGATGCTCAAGGCCTGGGAAAAGCTCGAGACCTTCATCGTGCAG
GACTTCCAGTGGACCGCAACCGCGCGCCACGCCGACATCGTCCTGCCGGCGACGACCTCC
TACGAGCGCAACGACATCGAGTCGGTGGGCGACTATTCGAACCGCGCCATCCTCGCGATG
AAGAAGGTGGTCGATCCGCTCTACGAGGCCCGGTCGGACTACGACATCTTCGCAGCCCTG
GCCGAGCGCCTGGGCAAGGGCGCCGAATTCACCGAAGGGCGCGACGAGATGGGGTGGATC
AGCTCGTTCTACGAGGCTGCGGTGAAGCAGGCGGAGTTCAAGAACGTGGCGATGCCGTCG
TTCGAGGATTTCTGGTCGGAAGGGATCGTCGAATTCCCGATCACCGAGGGCGCGAACTTC
GTCCGCTATGCCGACTTCCGCGAGGATCCGCTGTTCAACCCGCTCGGCACGCCCTCGGGC
CTGATCGAGATCTACTCGAAGAACATCGAGAAGATGGGCTATGACGATTGCCCGGCCCAT
CCGACCTGGATGGAACCGGCCGAGCGTCTCGGCGGGGCAGGGGCGAAATATCCGCTCCAT
GTCGTGGCGAGCCATCCGAAGTCGCGGCTGCACTCGCAGCTGAACGGCACCTCGCTGCGC
GACCTCTATGCGGTGGCGGGGCACGAACCCTGCCTCATCAACCCCGCCGATGCGGCCGCG
CGCGGCATCGCGGACGGCGATGTGCTGCGGGTGTTCAACGACCGCGGGCAGATCCTCGTG
GGGGCGAAGGTCAGCGACGCGGTGATGCCGGGCGCGATCCAGATCTACGAGGGCGGCTGG
TACGACCCGCTCGATCCCTCGGAGGAGGGCACGCTCGACAAGTACGGCGACGTGAACGTG
CTGTCGCTCGATGTCGGCACCTCGAAGCTGGCGCAGGGCAACTGCGGCCAGACCATCCTC
GCGGATGTCGAGAAATATGCGGGCGCGCCGGTGACGGTGACCGTGTTCGACACGCCGAAG
GGCGCCTGA

# Drug_Target_8_General_Function:
Energy production and conversion

# Drug_Target_8_General_References:
7625833	Barber MJ, Van Valkenburgh H, Trimboli AJ, Pollock VV, Neame PJ, Bastian NR: The amino acid sequence of Rhodobacter sphaeroides dimethyl sulfoxide reductase. Arch Biochem Biophys. 1995 Jul 10;320(2):266-75.
8534974	Yamamoto I, Wada N, Ujiiye T, Tachibana M, Matsuzaki M, Kajiwara H, Watanabe Y, Hirano H, Okubo A, Satoh T, et al.: Cloning and nucleotide sequence of the gene encoding dimethyl sulfoxide reductase from Rhodobacter sphaeroides f. sp. denitrificans. Biosci Biotechnol Biochem. 1995 Oct;59(10):1850-5.
8645727	Hilton JC, Rajagopalan KV: Molecular cloning of dimethyl sulfoxide reductase from Rhodobacter sphaeroides. Biochim Biophys Acta. 1996 May 23;1294(2):111-4.
8658134	Schindelin H, Kisker C, Hilton J, Rajagopalan KV, Rees DC: Crystal structure of DMSO reductase: redox-linked changes in molybdopterin coordination. Science. 1996 Jun 14;272(5268):1615-21.

# Drug_Target_8_HGNC_ID:
Not Available

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
2705

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
89208

# Drug_Target_8_Name:
Dimethyl sulfoxide reductase

# Drug_Target_8_Number_of_Residues:
822

# Drug_Target_8_PDB_ID:
1EU1

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF00384	Molybdopterin
PF01568	Molydop_binding

# Drug_Target_8_Protein_Sequence:
>Dimethyl sulfoxide reductase precursor
MTKLSGQELHAELSRRAFLSYTAAVGALGLCGTSLLAQGARAEGLANGEVMSGCHWGVFK
ARVENGRAVAFEPWDKDPAPSHQLPGVLDSIYSPTRIKYPMVRREFLEKGVNADRSTRGN
GDFVRVTWDEALDLVARELKRVQESYGPTGTFGGSYGWKSPGRLHNCQVLMRRALNLAGG
FVNSSGDYSTAAAQIIMPHVMGTLEVYEQQTAWPVVVENTDLMVFWAADPMKTNEIGWVI
PDHGAYAGMKALKEKGTRVICINPVRTETADYFGADVVSPRPQTDVALMLGMAHTLYSED
LHDKDFLENCTTGFDLFAAYLTGESDGTPKTAEWAAEICGLPAEQIRELARSFVAGRTML
AAGWSIQRMHHGEQAHWMLVTLASMIGQIGLPGGGFGLSYHYSNGGSPTSDGPALGGISD
GGKAVEGAAWLSESGATSIPCARVVDMLLNPGGEFQFNGATATYPDVKLAYWAGGNPFAH
HQDRNRMLKAWEKLETFIVQDFQWTATARHADIVLPATTSYERNDIESVGDYSNRAILAM
KKVVDPLYEARSDYDIFAALAERLGKGAEFTEGRDEMGWISSFYEAAVKQAEFKNVAMPS
FEDFWSEGIVEFPITEGANFVRYADFREDPLFNPLGTPSGLIEIYSKNIEKMGYDDCPAH
PTWMEPAERLGGAGAKYPLHVVASHPKSRLHSQLNGTSLRDLYAVAGHEPCLINPADAAA
RGIADGDVLRVFNDRGQILVGAKVSDAVMPGAIQIYEGGWYDPLDPSEEGTLDKYGDVNV
LSLDVGTSKLAQGNCGQTILADVEKYAGAPVTVTVFDTPKGA

# Drug_Target_8_Reaction:
Not Available

# Drug_Target_8_Signals:
1-42

# Drug_Target_8_Specific_Function:
Terminal reductase during anaerobic growth on various sulfoxide and N-oxide compounds

# Drug_Target_8_SwissProt_ID:
Q57366

# Drug_Target_8_SwissProt_Name:
DMSA_RHOSH

# Drug_Target_8_Synonyms:
DMSO reductase
DMSOR
Dimethyl sulfoxide reductase precursor
EC 1.8.99.-

# Drug_Target_8_Theoretical_pI:
4.87

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Cytoplasm

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
PRDX2

# Drug_Target_9_GenBank_ID_Gene:
Z22548

# Drug_Target_9_GenBank_ID_Protein:
438069

# Drug_Target_9_GeneCard_ID:
PRDX2

# Drug_Target_9_Gene_Name:
PRDX2

# Drug_Target_9_Gene_Sequence:
>597 bp
ATGGCCTCCGGTAACGCGCGCATCGGAAAGCCAGCCCCTGACTTCAAGGCCACAGCGGTG
GTTGATGGCGCCTTCAAAGAGGTGAAGCTGTCGGACTACAAAGGGAAGTACGTGGTCCTC
TTTTTCTACCCTCTGGACTTCACTTTTGTGTGCCCCACCGAGATCATCGCGTTCACAACC
GTGAAGAGGACTTCCGCAAAGCTGGGCTGTGAAGTGCTGGGCGTCTCGGTGGACTCTCAG
TTCACCCACCTGGCTTGGATCAACACCCCCCGGAAAGAGGGAGGCTTGGGCCCCTTGAAC
ATCCCCCTGCTTGCTGACGTGACCAGACGCTTGTCTGAGGATTACGGCGTGCTGAAAAAC
GATGAGGGCATTGCTTACAGGGGCCTCTTTATCATCGATGGCAAGGGTGTCCTTCGCCAG
ATCACTGTTAATGATTTGCCTGTGGGACGCTCCGTGGATGAGGCTCTGCGGCTGGTCCAG
GCCTTCCAGTACACAGACGAGCATGGGGAAGTTTGTCCGGCTGCTTGGAAGCCTGGACGT
GACACGATTAAGCCGAACGTGGATGACAGCAAGGAATATTTCTCCAAACACAATTAG

# Drug_Target_9_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_9_General_References:
11904290	Rabilloud T, Heller M, Gasnier F, Luche S, Rey C, Aebersold R, Benahmed M, Louisot P, Lunardi J: Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. J Biol Chem. 2002 May 31;277(22):19396-401. Epub 2002 Mar 19.
1286667	Rasmussen HH, van Damme J, Puype M, Gesser B, Celis JE, Vandekerckhove J: Microsequences of 145 proteins recorded in the two-dimensional gel protein database of normal human epidermal keratinocytes. Electrophoresis. 1992 Dec;13(12):960-9.
8026862	Shau H, Butterfield LH, Chiu R, Kim A: Cloning and sequence analysis of candidate human natural killer-enhancing factor genes. Immunogenetics. 1994;40(2):129-34.
8144038	Lim YS, Cha MK, Kim HK, Kim IH: The thiol-specific antioxidant protein from human brain: gene cloning and analysis of conserved cysteine regions. Gene. 1994 Mar 25;140(2):279-84.
8313871	Golaz O, Hughes GJ, Frutiger S, Paquet N, Bairoch A, Pasquali C, Sanchez JC, Tissot JD, Appel RD, Walzer C, et al.: Plasma and red blood cell protein maps: update 1993. Electrophoresis. 1993 Nov;14(11):1223-31.
9150948	Ji H, Reid GE, Moritz RL, Eddes JS, Burgess AW, Simpson RJ: A two-dimensional gel database of human colon carcinoma proteins. Electrophoresis. 1997 Mar-Apr;18(3-4):605-13.

# Drug_Target_9_HGNC_ID:
HGNC:9353

# Drug_Target_9_HPRD_ID:
02763

# Drug_Target_9_ID:
3599

# Drug_Target_9_Locus:
19p13.2

# Drug_Target_9_Molecular_Weight:
21892

# Drug_Target_9_Name:
Peroxiredoxin-2

# Drug_Target_9_Number_of_Residues:
198

# Drug_Target_9_PDB_ID:
1QMV

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF00578	AhpC-TSA

# Drug_Target_9_Protein_Sequence:
>Peroxiredoxin-2
MASGNARIGKPAPDFKATAVVDGAFKEVKLSDYKGKYVVLFFYPLDFTFVCPTEIIAFSN
RAEDFRKLGCEVLGVSVDSQFTHLAWINTPRKEGGLGPLNIPLLADVTRRLSEDYGVLKT
DEGIAYRGLFIIDGKGVLRQITVNDLPVGRSVDEALRLVQAFQYTDEHGEVCPAGWKPGS
DTIKPNVDDSKEYFSKHN

# Drug_Target_9_Reaction:
2 R'-SH + ROOH = R'-S-S-R' + H2O + ROH

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
Involved in redox regulation of the cell. Reduces peroxides with reducing equivalents provided through the thioredoxin system. It is not able to receive electrons from glutaredoxin. May play an important role in eliminating peroxides generated during metabolism. Might participate in the signaling cascades of growth factors and tumor necrosis factor-alpha by regulating the intracellular concentrations of H(2)O(2)

# Drug_Target_9_SwissProt_ID:
P32119

# Drug_Target_9_SwissProt_Name:
PRDX2_HUMAN

# Drug_Target_9_Synonyms:
EC 1.11.1.15
NKEF-B
Natural killer cell-enhancing factor B
PRP
TSA
Thiol-specific antioxidant protein
Thioredoxin peroxidase 1
Thioredoxin-dependent peroxide reductase 1

# Drug_Target_9_Theoretical_pI:
5.75

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB02153
